Cargando…
Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRP...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/ https://www.ncbi.nlm.nih.gov/pubmed/30732140 http://dx.doi.org/10.1097/MD.0000000000014254 |
_version_ | 1783396380649193472 |
---|---|
author | Zhang, Xuebao Liu, Chu Li, Kui Wang, Ke Zhang, Qiqiang Cui, Yuanshan |
author_facet | Zhang, Xuebao Liu, Chu Li, Kui Wang, Ke Zhang, Qiqiang Cui, Yuanshan |
author_sort | Zhang, Xuebao |
collection | PubMed |
description | Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated. Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P = .25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P < .001), anaemia (P < .001), thrombocytopenia (P < .001), and diarrhea (P = .002). Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo. |
format | Online Article Text |
id | pubmed-6380863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63808632019-03-11 Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer Zhang, Xuebao Liu, Chu Li, Kui Wang, Ke Zhang, Qiqiang Cui, Yuanshan Medicine (Baltimore) Research Article Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated. Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P = .25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P < .001), anaemia (P < .001), thrombocytopenia (P < .001), and diarrhea (P = .002). Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo. Wolters Kluwer Health 2019-02-08 /pmc/articles/PMC6380863/ /pubmed/30732140 http://dx.doi.org/10.1097/MD.0000000000014254 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Zhang, Xuebao Liu, Chu Li, Kui Wang, Ke Zhang, Qiqiang Cui, Yuanshan Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
title | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
title_full | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
title_fullStr | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
title_full_unstemmed | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
title_short | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
title_sort | meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/ https://www.ncbi.nlm.nih.gov/pubmed/30732140 http://dx.doi.org/10.1097/MD.0000000000014254 |
work_keys_str_mv | AT zhangxuebao metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer AT liuchu metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer AT likui metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer AT wangke metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer AT zhangqiqiang metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer AT cuiyuanshan metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer |